Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ulotaront
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II/ Phase III
Sponsor : Otsuka America Pharmaceutical, Inc.
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SEP-363856 (ulotaront) is a TAAR1 agonist with 5-HT1A agonist activity, is currently under investigation for the treatment of schizophrenia, generalized anxiety disorder and the adjunctive treatment of MDD with additional indications under consideration.
Product Name : SEP-363856
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 26, 2023
Lead Product(s) : Ulotaront
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II/ Phase III
Sponsor : Otsuka America Pharmaceutical, Inc.
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Arformoterol Tartrate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Approved FDF
Sponsor : Lupin Ltd
Deal Size : $75.0 million
Deal Type : Acquisition
Lupin Signs Agreement to Acquire Two Inhalation Brands from Sunovion
Details : The acquisition of Brovana® (arformoterol tartrate) Inhalation Solution and Xopenex HFA® (levalbuterol tartrate) Inhalation Aerosol brands expands Lupin’s portfolio of inhalation products in the U.S. and strengthens the company’s presence in the re...
Product Name : Brovana
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 20, 2022
Lead Product(s) : Arformoterol Tartrate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved FDF
Sponsor : Lupin Ltd
Deal Size : $75.0 million
Deal Type : Acquisition
Lead Product(s) : Amisulpride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Otsuka Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Sep-4199, enhance 5-HT7 receptor antagonist activity and reduce dopamine D2 receptor antagonist activity is in SEP380-301, Phase 3 clinical development for treatment of major depressive episodes associated with bipolar I disorder also showed positive Pha...
Product Name : Sep-4199
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 02, 2022
Lead Product(s) : Amisulpride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Otsuka Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ulotaront
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Otsuka Pharmaceutical
Deal Size : $890.0 million
Deal Type : Collaboration
Details : The collaboration will focus on solutions to address areas of unmet medical need by advancing four promising compounds―ulotaront (SEP-363856), SEP-4199, SEP-378614 and SEP-380135―that address serious neuropsychiatric disorders.
Product Name : SEP-363856
Product Type : Other Small Molecule
Upfront Cash : $270.0 million
September 30, 2021
Lead Product(s) : Ulotaront
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Otsuka Pharmaceutical
Deal Size : $890.0 million
Deal Type : Collaboration
Lead Product(s) : Apomorphine Hydrochloride
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Bial
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the terms of the agreement, BIAL will be responsible for regulatory approvals and submissions, including interactions with the European Medicines Agency (EMA) for APL-130277, which is currently in Phase 3 clinical development in Europe.
Product Name : Kynmobi
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
February 09, 2021
Lead Product(s) : Apomorphine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Bial
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Urovant Sciences Announces Co-Promotion Agreement for Vibegron with Sunovion Pharmaceuticals
Details : Under the terms of the agreement, Sunovion will deploy its multi-specialty sales force to bring vibegron to primary care physicians (PCP). In support of this effort, Sunovion will provide sales and marketing activities targeting the PCP segment through M...
Product Name : Gemtesa
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 10, 2020
Lead Product(s) : Apomorphine Hydrochloride
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Sunovion Pharmaceuticalsannounced today that Health Canada has approved KYNMOBI™ (apomorphine HCI) soluble film for the acute, intermittent treatment of OFF episodes in patients with Parkinson’s disease (PD).
Product Name : Kynmobi
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 15, 2020
Lead Product(s) : Apomorphine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Apomorphine Hydrochloride
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : In a Phase 3 study, patients with Parkinson’s disease treated with KYNMOBI experienced significant improvements in motor symptoms at 30 minutes, compared to placebo.
Product Name : Kynmobi
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 21, 2020
Lead Product(s) : Apomorphine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dasotraline
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Sunovion Ditches Once-Rejected ADHD, Binge Eating Program
Details : Sunovion has withdrawn the New Drug Applications for dasotraline, a novel dopamine and norepinephrine reuptake inhibitor, for the treatment of moderate-to-severe binge eating disorder (BED) and attention deficit hyperactivity disorder (ADHD).
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 13, 2020
Lead Product(s) : Dasotraline
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ulotaront
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Significantly greater improvement in the Positive and Negative Symptom Scale was demonstrated in schizophrenia patients treated with SEP-363856, a TAAR1 agonist, compared to placebo.
Product Name : SEP-363856
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 15, 2020
Lead Product(s) : Ulotaront
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable